0 CHECKOUT

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015

  • ID: 3384959
  • July 2015
  • 59 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Cebix Incorporated
  • Pfizer Inc.
  • ViroMed Co., Ltd.
  • MORE

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015

Summary

The report ‘Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015’, provides an overview of the Diabetic Peripheral Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Cebix Incorporated
  • Pfizer Inc.
  • ViroMed Co., Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Diabetic Peripheral Neuropathy Overview
Therapeutics Development
Pipeline Products for Diabetic Peripheral Neuropathy - Overview
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Peripheral Neuropathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Peripheral Neuropathy - Products under Development by Companies
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Astellas Pharma Inc.
Cebix Incorporated
Pfizer Inc.
ViroMed Co., Ltd.
Diabetic Peripheral Neuropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antimunocel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-8477 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNV-222 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBX-129801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-05089771 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Peripheral Neuropathy - Recent Pipeline Updates
Diabetic Peripheral Neuropathy - Dormant Projects
Diabetic Peripheral Neuropathy - Discontinued Products
Diabetic Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Diabetic Peripheral Neuropathy - Pipeline by Acorda Therapeutics, Inc., H2 2015
Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H2 2015
Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H2 2015
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H2 2015
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015
Diabetic Peripheral Neuropathy - Dormant Projects, H2 2015
Diabetic Peripheral Neuropathy - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Acorda Therapeutics, Inc.
Astellas Pharma Inc.
Cebix Incorporated
Pfizer Inc.
ViroMed Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.